Home » Clinical Trials » Leukemia
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Official Title: Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial
The main purpose of this study is to see if ofatumumab with methylprednisolone followed by
additional treatment with ofatumumab and lenalidomide can help people with Chronic
Lymphocytic Leukemia (CLL) get rid of their CLL for a long period of time. Researchers also
want to find out if the combination of ofatumumab with methylprednisolone followed by
additional treatment with ofatumumab and lenalidomide is safe and tolerable.
Phase: Phase 2
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
||H. Lee Moffitt Cancer Center and Research Institute
Elyce Turba, RN
Celeste Bello, M.D.
Jeffrey Lancet, M.D.
Lubomir Sokol, M.D., Ph.D.
Javier Pinilla-Ibarz, M.D., Ph.D.
Eduardo Sotomayor, M.D.
Bijal Shah, M.D.
Date Last Changed: April 26, 2013